Organon & Co. (NYSE:OGN) Receives Average Rating of "Hold" from Analysts

Shares of Organon & Co. (NYSE:OGN - Get Free Report) have been assigned an average recommendation of "Hold" from the seven ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $20.80.

Several brokerages have issued reports on OGN. Barclays dropped their target price on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a report on Friday, February 14th. TD Cowen upgraded shares of Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. Finally, Morgan Stanley reduced their target price on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research note on Friday, February 14th.

Organon & Co. Price Performance

Shares of OGN stock traded up $0.38 on Tuesday, reaching $15.34. 3,034,112 shares of the company were exchanged, compared to its average volume of 2,344,894. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The business has a 50-day moving average price of $15.46 and a 200 day moving average price of $16.78. The company has a market cap of $3.96 billion, a price-to-earnings ratio of 4.61, a P/E/G ratio of 0.90 and a beta of 0.76.

Remove Ads

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). The firm had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. Equities research analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 7.30%. The ex-dividend date was Monday, February 24th. Organon & Co.'s dividend payout ratio (DPR) is presently 33.63%.

Institutional Investors Weigh In On Organon & Co.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in Organon & Co. by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company's stock valued at $453,593,000 after purchasing an additional 218,165 shares during the last quarter. Pacer Advisors Inc. raised its holdings in shares of Organon & Co. by 94,482.1% in the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock valued at $166,391,000 after buying an additional 11,140,388 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Organon & Co. by 1.4% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 9,895,067 shares of the company's stock valued at $147,634,000 after buying an additional 136,760 shares during the period. LSV Asset Management lifted its stake in Organon & Co. by 0.4% during the 4th quarter. LSV Asset Management now owns 7,525,076 shares of the company's stock worth $112,274,000 after acquiring an additional 30,557 shares in the last quarter. Finally, Deprince Race & Zollo Inc. boosted its holdings in Organon & Co. by 7.0% during the 4th quarter. Deprince Race & Zollo Inc. now owns 4,729,258 shares of the company's stock valued at $70,561,000 after acquiring an additional 308,267 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.